

## Clinical Biochem 2 BMS302 Learning Objectives Answered

### **MODULE ONE : TOPIC ONE**

**write the equations illustrating the competition between labelled and unlabelled antigen to a specific antibody**




**identify experimental conditions for competitive binding immunoassay**

1. There must be fixed concentrations of antibody (Ab) and labelled antigen (Ag\*) – the only variable is the amount of unlabelled antigen (Ag)
2. A limiting amount of antibody (Ab) – that is there must be less antibody than there is labelled antigen. This means that the labelled Ag\* and the unlabelled Ag will need to compete for the binding to the limiting amount of Ab.

**describe the relationship between the amount of labelled antigen complexed to antibody (the label bound) and the concentration of unlabelled antigen.**

- At low levels of unlabelled antigen (Ag) – which is the variable – higher levels of labelled antigen (Ag\*) will bind to the antibody (Ab).
- As unlabelled antigen (Ag) levels increase – less labelled antigen (Ag\*) will bind to the antibody (Ab).
- This means there is an inverse relationship between the levels of Ag\* bound and the levels of Ag.
- Standards must be made with unbound antigen (Ag) and run in parallel and a standard curve plotted.



The more unlabelled antigen (Ag) added the less labelled Ag\* binds to Ab.

### **distinguish between antigens, immunogens and haptens.**

- Antigens: molecules that bind to specific antibodies.
- Immunogens: substances that induce antibody formation.
- Haptens: non-immunogenic molecules which become immunogenic after attachment to a carrier.

NB. The bigger the molecule the more immunogenic it is likely to be. Smaller molecules only become immunogenic after attachment to a carrier – usually a protein.

### **describe conjugation and identify the range of carrier proteins for conjugation to haptens**

- Conjugation is the attachment of a small non-immunogenic compound (hapten) to a carrier protein in order to make it immunogenic.
- The bond must be stable and this is achieved through covalent linkages via a conjugation reaction.
- Protein carriers include
  - globulin fractions
  - albumin
  - haemocyanin
  - ovalbumin
  - fibrinogen
- The hapten attaches to the amino acid side chains on the surface of the carrier protein. For eg.
  - $\epsilon$ -amino groups of lysine
  - phenolic hydroxyl groups of tyrosine residues
  - sulphhydryl groups of cysteine
  - imidazole groups of histidine residues
- Conjugation should take place in an area of the hapten that is least important for immunological recognition.
- Conjugation should not overly change the tertiary structure of the protein.

### **explain the procedures used to raise polyvalent antisera**

NB. Polyvalent antisera is not used much anymore – not sensitive or specific enough

High affinity anti-hapten antibodies are raised from rabbits, guinea pigs, goats, mice and sheep.

Antigen is administered to young fully developed animals in multiple small doses.

### **define a monoclonal antibody and describe hybridoma technology in production of monoclonal antibodies**

- Monoclonal antibodies are a single homogenous (all the same) population of antibodies that are highly specific for a SINGLE epitope on a multivalent antigen.
- Immunisation with a single pure antigen triggers a population of lymphocytes that each produce a single antibody.
- If you take one of these antibody forming cells you can produce a clone in vitro which will produce a large amount of the monoclonal antibody you require.
- Because the lymphocytes cannot grow in tissue culture due to the Hayflick limit, a hybridoma is created – a hybrid of the antibody producing lymphocyte and a multiple myeloma cell.
- Hybridomas have the following characteristics
  - Ability to constantly divide in a tissue culture – due to the myeloma cells potential immortal qualities.
  - Ability to produce a single antibody – because of the lymphocyte.

### **define antibody titre and know its importance in an immunoassay**


- Antibody Titre: is the final dilution of antibody used in the assay when the antigen is present. In other words it is the appropriate dilution that allows the antibody to be limited.

### **distinguish between affinity and avidity of antigen-antibody binding**

- Affinity: the strength of a SINGLE non-covalent Ab-Ag bond
- Avidity: is the strength of the multiple binding between Ag and Ab.
- Sensitivity: the minimum detection limit of an assay. The least concentration of Ag which can be distinguished from a sample that contains no Ag.

### **define specificity and cross-reactivity in relation to antigen-antibody interaction and know the importance in relation to immunoassays. describe the experimental methods to assess the extent of cross-reactivity.**

- Specificity: the capacity of an antiserum to recognise its own antigen in the presence of others.
- Cross reactivity: is when other antigens bind to an antibody that it is not directed towards. (Antigen A will be displaced by Antigen B)
  - FSH, TSH, LH, hCG all have different beta chains but similar alpha chains and this can result in cross reactivity.
  - To overcome these issues a competition assay between a labelled version of the antigen, an unlabelled version, and then some known cross reacting molecules.



- If there is no cross reactivity – increasing concentration of cross reacting molecules will have no effect on the amount of lable bound to antibody.
- If there is 100% cross reactivity the cross reacting molecule will follow the displacement line for the actual Ag.
- Most cross reacting molecules will be somewhere in the middle.
- To work out the midrange (the concentration of cross reacting molecule needed to reduce labelled antigen binding to 50% of its original level)
  - Draw a horizontal line across from the small mark midway down the vertical scale and see where it cuts the experimental lines.
  - Draw vertical lines down from these intersection points to the horizontal axis.
  - Compare this figure with the concentration of antigen required to cause a similar 50% reduction.

### **distinguish between heterogeneous and homogeneous immunoassays**

**NB.** For most immunoassays, the parameter that is always measured is the amount of labelled antigen ( $Ag^*$ ) which is bound to the antibody.

- Heterogenous assays
  - Binding of the  $Ab-Ag^*$  does not change the signal
  - Separation of the  $Ab-Ag^*$  and the free  $Ag$  and  $Ag^*$  is required.
  - Difficult to automate